LETTER Glaucoma symptom scale: is it a reliable measure of symptoms in glaucoma patients? Glaucoma is the leading cause of irrevers- ible blindness worldwide after cataract and accounts for 10% of the worlds blind. 1 Although patients with acute angle closure glaucoma are symptomatic, those with other forms of glaucoma (at least in the early stages) usually do not experience many symptoms, thereby, resulting in the disease often going unnoticed with pos- sible progression. In some cases, patients with uctuating levels of intraocular pres- sure may experience blurred vision and see haloes around lights. The Glaucoma Symptom Scale (GSS) was developed to assess ophthalmic symptoms experienced by patients with glaucoma. 2 The GSS com- prises 10 ocular symptoms, of which six are non-visual and four are visual. The non-visual symptoms include burning/ smarting/stinging, tearing, dryness, itching, soreness/tiredness, and feeling of something in the eye. The visual symp- toms include blurry/dim vision, hard to see in daylight, hard to see in darkness, and halos around lights. The GSS is unique in that it assesses symptoms as compared with visual functioning by other glaucoma-specic questionnaires. Like most questionnaires in ophthalmology, the GSS was also developed using traditional psychometric methods, that is, the classical test theory (CTT). 3 The limitations of CTT have been well acknowledged. A major shortcoming of CTT pertains to its scoring assumptions: Likert or summary scoring in which the scores are calculated from simple additions of ordinal values assigned to response categories for each item. Such a method of scoring is errone- ous as it assumes that response categories are equidistant on a measurement scale and that all questions are of equal dif- culty, and thereby treating the whole ques- tionnaire as interval scale based on ordinal level scoring. This limitation is overcome by the use of item response theory, in par- ticular Rasch analysis, that makes use of interval-level data. A particularly import- ant advantage is the fact that when ques- tionnaire data t the stringent requirements of the Rasch model, the ordinal scores generated by summing scores for all items (summary score) can be transformed into interval level or linear measurements. This means that by using a Rasch-based scale, symptoms can then be measured on a linear scale. Additionally, Rasch analysis helps improve sensitivity to change by reducing noise in measurement and so has advan- tages for outcomes research. 4 Recently, the GSS was subjected to Rasch analysis in an Australian Glaucoma population. 5 Although the investigators found the GSS to have good psychometric characteristics, an important propertytargeting was suboptimal indicating that the GSS was unable to assess fully the range of symp- toms in their sample which perhaps did not possess the severity of visual eld (VF) loss to experience the symptoms. Given this result, we investigated the psy- chometric properties of the GSS using Rasch analysis in an Indian Glaucoma population with more severe forms of glaucoma (moderate to severe VF loss). Records of adult patients with estab- lished bilateral primary glaucoma and glaucomatous VF loss (using Humphrey Visual Fields Analyzer 24-2 program) were prescreened for eligibility in the study. Given our aim, we prescreened and selected consecutive records of those patients with moderate (612 dB) or severe VF loss (<12 dB) in better eye for inclusion and those with diffuse reduction in sensitivity (as this could be related to cataract and affect the results) were excluded. Eligible patients were invited to participate in the study during their routine follow-up visit to L V Prasad Eye Institute, Hyderabad, India between November 2010 and January 2011. The GSS was administered to 129 consecutive eligible participants on the day of their appointment. While a little over one-half (55%) self-administered the GSS, trained interviewers administered it to the remain- ing participants. The Ethics Committee for human research at the L V Prasad Eye Institute approved the study and consent- ing participants provided written informed consent. Rasch analysis was per- formed using Winsteps software. The mean (±SD) age of the participants was 60.9±13.05 years (range, 20 87 years) and 69% were male. The median duration since diagnosis was 7.0 years (range, 158 years). One-half of the participants (49.6%) had primary open angle glaucoma; males constituted 83% of this group. By comparison, only 38.8% had primary angle closure glau- coma; over one-half (54%) were females. This latter nding is in accordance with a clinic-based 6 and two population-based studies from India, the Andhra Pradesh Eye Disease Study 7 and the Chennai Glaucoma Study. 8 The median presenting better and worse eye acuity (logMAR) was 0.0 (Snellen equivalent, 20/20) and 0.30 (Snellen equivalent, 20/40) respectively. The mean (±SD) intraocular pressures were 15.1±4.3 and 15.8±6.5 mm Hg in the right and left eyes respectively. Participants did not use the rating scale as was intended to, requiring reduction in number of categories from ve to three. However, person separation reliability was inadequate suggesting that the GSS could not reliably differentiate among the parti- cipantssymptoms (table 1). The GSS was poorly targeted with most participants not bothered by symptoms in the GSS. All items t the Rasch model and unidimen- sionality was present, implying that GSS was a unidimensional measure of glau- coma symptoms. The GSS is unable to discriminate among glaucoma patients based on their symptoms in India. Based on the subopti- mal performance of the GSS as demon- strated in the present study and that of Lamoureux et al, 5 we do not recommend the use of GSS to assess patients with glaucoma having moderate to severe eld loss (but with relatively good central vision). Given these ndings of the GSS and the lack of glaucoma symptom- specic questionnaires, there may be a need to develop one by researchers in future. A superior approach, however, would be creation of an item bank of glaucoma symptoms items, inclusive of GSS, and utilise computer-adaptive testing for measurement. Table 1 Overall performance of the Glaucoma Symptom Scale Parameters Values Ideal values Number of items 10 No. of misfitting items 0 0 Person separation reliability* 0.68 >0.80 Mean item location 0 0 Mean person location1.33 0 Principal components analysis(eigenvalue for first contrast) 1.8 <2.0 *Indicates measurement precisionability to discriminate among participants based on their symptoms and values >0.80 suggest that the questionnaire can discriminate among at least three strata of participants based on the underlying construct. Difference between person and item location (usually set at zero) indicates targeting of item difficulty (ie, bothersome) to participantssymptoms. An assessment of unidimensionality. Br J Ophthalmol Month 2012 Vol 0 No 0 1 PostScript BJO Online First, published on November 30, 2012 as 10.1136/bjophthalmol-2012-302041 Copyright Article author (or their employer) 2012. Produced by BMJ Publishing Group Ltd under licence. group.bmj.com on November 4, 2016 - Published by http://bjo.bmj.com/ Downloaded from